Literature DB >> 30884330

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Fang Chen1, Netanel Tzarum2, Ian A Wilson3, Mansun Law4.   

Abstract

Broadly neutralizing antibodies (bnAbs) are potential therapeutic molecules and valuable tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody responses to conserved epitopes can be highly convergent at the molecular level. Human antibodies targeting a number of viral antigens have often been found to utilize a restricted set of immunoglobulin germline genes in different individuals. Here we review recent knowledge on VH1-69-encoded antibodies in antiviral responses to influenza virus, HCV, and HIV-1. These antibodies share common genetic and structural features, and often develop neutralizing activity against a broad spectrum of viral strains. Understanding the genetic and structural characteristics of such antibodies and the target epitopes should help advance novel strategies to elicit bnAbs through vaccination.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30884330      PMCID: PMC7266006          DOI: 10.1016/j.coviro.2019.02.004

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  110 in total

1.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

Review 2.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

3.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

4.  HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.

Authors:  Wilton B Williams; Hua-Xin Liao; M Anthony Moody; Thomas B Kepler; S Munir Alam; Feng Gao; Kevin Wiehe; Ashley M Trama; Kathryn Jones; Ruijun Zhang; Hongshuo Song; Dawn J Marshall; John F Whitesides; Kaitlin Sawatzki; Axin Hua; Pinghuang Liu; Matthew Z Tay; Kelly E Seaton; Xiaoying Shen; Andrew Foulger; Krissey E Lloyd; Robert Parks; Justin Pollara; Guido Ferrari; Jae-Sung Yu; Nathan Vandergrift; David C Montefiori; Magdalena E Sobieszczyk; Scott Hammer; Shelly Karuna; Peter Gilbert; Doug Grove; Nicole Grunenberg; M Juliana McElrath; John R Mascola; Richard A Koup; Lawrence Corey; Gary J Nabel; Cecilia Morgan; Gavin Churchyard; Janine Maenza; Michael Keefer; Barney S Graham; Lindsey R Baden; Georgia D Tomaras; Barton F Haynes
Journal:  Science       Date:  2015-07-30       Impact factor: 47.728

5.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

6.  Immunoglobulins: 25 years of immunoinformatics and IMGT-ONTOLOGY.

Authors:  Marie-Paule Lefranc
Journal:  Biomolecules       Date:  2014-12-16

Review 7.  Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design.

Authors:  Chaim A Schramm; Daniel C Douek
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

8.  Structural and genetic basis for development of broadly neutralizing influenza antibodies.

Authors:  Daniel Lingwood; Patrick M McTamney; Hadi M Yassine; James R R Whittle; Xiaoti Guo; Jeffrey C Boyington; Chih-Jen Wei; Gary J Nabel
Journal:  Nature       Date:  2012-08-29       Impact factor: 49.962

9.  A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process.

Authors:  Roberto Bruni; Angela Costantino; Elena Tritarelli; Cinzia Marcantonio; Massimo Ciccozzi; Maria Rapicetta; Gamal El Sawaf; Alessandro Giuliani; Anna Rita Ciccaglione
Journal:  BMC Struct Biol       Date:  2009-07-29

10.  Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.

Authors:  Zelda Euler; Marit J van Gils; Brigitte D Boeser-Nunnink; Hanneke Schuitemaker; Daniëlle van Manen
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more
  42 in total

1.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

2.  A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.

Authors:  Chunyan Wang; Rien van Haperen; Javier Gutiérrez-Álvarez; Wentao Li; Nisreen M A Okba; Irina Albulescu; Ivy Widjaja; Brenda van Dieren; Raul Fernandez-Delgado; Isabel Sola; Daniel L Hurdiss; Olalekan Daramola; Frank Grosveld; Frank J M van Kuppeveld; Bart L Haagmans; Luis Enjuanes; Dubravka Drabek; Berend-Jan Bosch
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

3.  Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.

Authors:  Fang Chen; Kenna Nagy; Deborah Chavez; Shelby Willis; Ryan McBride; Erick Giang; Andrew Honda; Jens Bukh; Phillip Ordoukhanian; Jiang Zhu; Sharon Frey; Robert Lanford; Mansun Law
Journal:  Gastroenterology       Date:  2019-12-04       Impact factor: 22.682

4.  Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion.

Authors:  Eduardo Salinas; Maude Boisvert; Amit A Upadhyay; Nathalie Bédard; Sydney A Nelson; Julie Bruneau; Cynthia A Derdeyn; Joseph Marcotrigiano; Matthew J Evans; Steven E Bosinger; Naglaa H Shoukry; Arash Grakoui
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

5.  HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.

Authors:  Yu-Ru Lin; K Rachael Parks; Connor Weidle; Anika S Naidu; Arineh Khechaduri; Andrew O Riker; Brittany Takushi; Jung-Ho Chun; Andrew J Borst; David Veesler; Andrew Stuart; Parul Agrawal; Matthew Gray; Marie Pancera; Po-Ssu Huang; Leonidas Stamatatos
Journal:  Immunity       Date:  2020-10-13       Impact factor: 31.745

Review 6.  The Conformational States of the HIV-1 Envelope Glycoproteins.

Authors:  Qian Wang; Andrés Finzi; Joseph Sodroski
Journal:  Trends Microbiol       Date:  2020-05-14       Impact factor: 17.079

7.  Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins.

Authors:  Fang Chen; Netanel Tzarum; Xiaohe Lin; Erick Giang; Rodrigo Velázquez-Moctezuma; Elias H Augestad; Kenna Nagy; Linling He; Mayda Hernandez; Mallorie E Fouch; Ariadna Grinyó; Deborah Chavez; Benjamin J Doranz; Jannick Prentoe; Robyn L Stanfield; Robert Lanford; Jens Bukh; Ian A Wilson; Jiang Zhu; Mansun Law
Journal:  Immunity       Date:  2021-03-05       Impact factor: 31.745

8.  Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy.

Authors:  Xiaoyi Zhu; Fei Yu; Yanling Wu; Tianlei Ying
Journal:  Antib Ther       Date:  2021-05-17

Review 9.  From Structural Studies to HCV Vaccine Design.

Authors:  Itai Yechezkel; Mansun Law; Netanel Tzarum
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.818

Review 10.  Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity.

Authors:  Nicholas A Brasher; Anurag Adhikari; Andrew R Lloyd; Nicodemus Tedla; Rowena A Bull
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.